Entry point for public reimbursement Using the reduced off-patent price as a strong argument for increased access, Canada could become the first market with wide-scale reimbursement of existing primary care medicines, including GLP-1s for diabetes, to designate off-patent semaglutide as the first-line anti-obesity medication (AOM)
A: Its important to consult with your healthcare provider before stopping semaglutide
It was suggested that this association is related to the maternal polymorphisms in APAP detoxification mechanisms, namely in GST genes
Zhang B, Cheng Z, Chen J et al (2024) Efficacy and safety of mazdutide in Chinese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 2 trial
Lembo, D., Cavalli, R., & Panzanelli, P